1	COVID-19 vaccination was a rare potential etiology for cause of death after medicolegal autopsy. A Finnish
2	nationwide study.

4	Lasse Pakanen ^{1,2,*} , Tuomo Nieminen ³ , Paula Kuvaja ¹ , Hanna Nohynek ⁴ , Sirkka Goebeler ⁵ , Miia Artama ^{4,6} ,
5	Petteri Hovi ⁷

- 6 ¹ Forensic Medicine Unit, Finnish Institute for Health and Welfare, Oulu
- ⁷ ² Department of Forensic Medicine, Research Unit of Biomedicine and Internal Medicine, Medical Research
- 8 Center Oulu, University of Oulu
- 9 ³ Information Brokers, Finnish Institute for Health and Welfare, Helsinki
- ⁴ Infectious Disease Control and Vaccinations, Finnish Institute for Health and Welfare, Helsinki
- ⁵ Forensic Medicine Unit, Finnish Institute for Health and Welfare, Helsinki
- ⁶ Faculty of Social Sciences, Epidemiology, Tampere University, Tampere
- ⁷ Department of Public Health and Welfare, Population Health Unit, Finnish Institute for Health and Welfare,
- 14 Helsinki

15

16 * Corresponding author. Address: Forensic Medicine Unit, Finnish Institute for Health and Welfare, P.O.

```
17 Box 310, FI-90101 Oulu, Finland; e-mail: lasse.pakanen@thl.fi; tel.: +358 29 524 7906
```

- 19 Author contributions: L.P., T.N., P.K., H.N., S.G., and P.H. conceived and designed the study. L.P., P.K. and
- 20 S.G. conceptualized the gathering of cause-of-death investigation data. T.N., H.N., M.A., and P.H. curated
- 21 vaccination and risk factor data. L.P., T.N., and P.H. analyzed data, and prepared the manuscript. All authors
- 22 contributed to interpretation of findings, critical revision of the manuscript, and approved the final version.
- 23 Data availability: All data generated or analyzed during this study are included in this published article.

24 ABSTRACT

25 COVID-19 vaccinations began globally at the end of 2020. By the end of 2021, 9.8 million doses were given 26 in Finland. Regarding safety, most vaccine-related adverse reactions have been mild, but serious and lethal 27 ones have also occurred. Autopsies in post vaccination deaths may give insight to the extent of fatal health 28 conditions with potential COVID-19 vaccine etiology and provide new hypotheses of possible causalities 29 between vaccination and severe health conditions. We searched the complete documentation on all 30 medicolegal autopsies in Finland between December 2020 and December 2021 to assess how often the basis 31 for autopsy was a suspected fatal adverse reaction to COVID-19 vaccination, and whether vaccination 32 remained a potential etiology for any health condition determined as a cause of death after the autopsy. We 33 linked register-based data on individual COVID-19 vaccination course and pre-existing health conditions. 34 We found 428 autopsy cases with a mention of COVID-19 vaccination, and prior to autopsy, vaccination 35 was suspected to play a part in 76 deaths. Post autopsy, a forensic pathologist considered vaccination as a 36 potential etiology in five underlying and seven contributory causes of death. These included seven 37 thromboembolisms, two diabetic ketoacidoses, one myocarditis, one acute pancreatitis, and one eosinophilic 38 granulomatosis with polyangiitis. In relation to the number of vaccinations within Finland, a suspicion of 39 vaccine-related serious adverse reaction was rarely an indication for medicolegal autopsy. Even less 40 frequently was vaccination considered to play a part in the process leading to death, although considerable 41 doubt remains in the accuracy of individual considerations, and autopsy cannot definitively confirm causality 42 between vaccination and death. Regarding vaccination safety, continuing evaluation of suspected vaccine-43 related deaths is essential, and an autopsy should be part of the investigation when such a suspicion arises.

44

45 Keywords

46 COVID-19 vaccine, adverse event following immunization, adverse reaction, cause of death, medicolegal47 autopsy

48 Abbreviations: AEFI, adverse events following immunization; CVST, cerebral venous sinus thrombosis;

49 TTS, thrombosis with thrombocytopenia syndrome; VITT, vaccine-induced immune thrombotic

50 thrombocytopenia

51

52 INTRODUCTION

53 During the COVID-19 pandemic, fast development of vaccines created several products that efficiently 54 prevent severe illness and death caused by the SARS-CoV-2 virus (1). The vaccines were proven to be safe 55 enough to meet the agreed emergency use licensing criteria, and large-scale as well as long-term safety 56 follow-up was to be done only post licensure (2). Post-marketing safety surveillance has revealed rare severe 57 adverse events following immunization (AEFI, terminology used in this paper according to the European 58 Medicines Agency guideline (3), is presented in Table 1), with some considered to be truly caused by the 59 vaccines. The first serious adverse reactions were thromboembolic complications including cerebral venous 60 sinus thrombosis (CVST) and other unusual thrombotic events which were related to adenoviral vector 61 vaccine ChAdOx1 (Vaxzevria, AstraZeneca) as reported by European Medicines Agency in April, 2021 (4). 62 Subsequently, an association emerged between these thromboses and thrombocytopenia, as well as the 63 occurrence of anti-platelet factor 4 antibodies in the patients, and this syndrome was named vaccine-induced 64 immune thrombotic thrombocytopenia (VITT) (5), or thrombosis with thrombocytopenia syndrome (TTS) 65 (6). Notably, VITT is also considered an adverse reaction to another adenoviral vector vaccine, 66 Ad26.COV2.S (COVID-19 Vaccine Janssen, Janssen Group) (5, 7). Additionally, cases of myocarditis and 67 pericarditis have occurred shortly after vaccination, and these conditions have been shown to be associated 68 with mRNA vaccines BNT162b2 (Comirnaty, BioNTech-Pfizer), and mRNA-1273 (Spikevax, Moderna) in 69 several large epidemiological studies, especially in young men (8-10). However, though myocarditis is a 70 severe condition, reports in young men show relatively mild outcomes and no mortality associated with myocarditis shortly after vaccination (11-12). Furthermore, based on a population-based follow-up study of 71 72 vaccine-related myocarditis, deaths are very rare (13).

73 A vast amount of unconfirmed and misinterpreted data without epidemiological support regarding vaccine-74 related morbidity and mortality has been of great concern from the beginning of COVID-19 vaccinations 75 (14–15). For an individual who dies within days or weeks following vaccination, the causes of death should 76 be thoroughly examined on one hand because of individual legal protection, and, on the other hand, to reveal 77 potential severe health conditions following immunization. The key investigation in this regard is an autopsy, 78 either medicolegal or clinical. A growing number of autopsy case reports of deaths following COVID-19 79 vaccination have been published (e.g., systematic review by Sessa et al. (16)). However, few larger autopsy-80 based data have yet been published. The Finnish law requires that a medicolegal cause-of-death investigation 81 must be done when death is considered unexpected, or if it has been caused or suspected to have been caused 82 by non-natural causes such as medical treatment (Act on the Inquest Into the Cause of Death 459/1973). 83 Thus, a medicolegal autopsy is generally instructed by the police when a vaccination is suspected to play a 84 role in the process leading to death. 85 We set out to evaluate how often the basis for medicolegal autopsy was a suspected fatal adverse reaction to 86 COVID-19 vaccination in Finland, and we describe cases in which COVID-19 vaccination remained as a 87 potential etiology for a health condition considered as any cause of death after the autopsy. We also describe 88 those cases in which the forensic pathologist considered COVID-19 vaccination not to have any part in the 89 death process. We describe the medicolegal cause-of-death investigation procedure and discuss the 90 remaining uncertainties in both the accuracy of case-selection for assessment, and in determining the 91 potential vaccine etiology.

92

93 MATERIAL AND METHODS

94

95 COVID-19 vaccinations in Finland

96 Since the beginning of the SARS-CoV-2-virus pandemic in 2020, several COVID-19 vaccines have been

97 introduced to the market. In Finland, the first vaccines were given in December 2020. By the end of 2021,

98 9.8 million doses had been administered in the country (17), and nearly 90% of the population aged 12 years
99 or older had received at least one dose (18).

100

101	Initially prioritized groups for COVID-19 vaccinations were the elderly, adults with a risk for severe
102	COVID-19 disease, and health care workers. Vaccination was gradually extended during 2021 to cover the
103	whole adult population with priority by age group from older to younger, and finally to children over five
104	years old. By the end of 2021, five vaccine products had gained conditional marketing authorization:
105	BNT162b2 on Dec 21, 2020; mRNA-1273 on Jan 6, 2021; ChAdOx1 on Jan 29, 2021; Ad26.COV2.S on
106	Mar 11, 2021; and NVX-CoV2373 (Nuvaxovid, Novavax) on Dec 20, 2021 (19). Due to safety concerns
107	related to coagulation disorders, the use of ChAdOx1 ceased on Mar 19, 2021 for those younger than 65
108	years, and altogether on Nov 30, 2021 (20). Because of the suspected relationship of mRNA-1273 and
109	myocarditis and pericarditis, the use of this vaccine ceased for men under 30 years of age on Oct 7, 2021
110	(21). All vaccinations given in Finland are recorded in electronic health record systems and collected to the
111	National Vaccination Register (22).

112

113 Medicolegal cause-of-death investigation process in suspected vaccine-related deaths in Finland

114

115 If a suspicion of a relationship between vaccination and death arises, the police instruct a medicolegal 116 autopsy. Suspicions can be based on information from next-of-kin, from treating clinicians, from police 117 investigation and/or in consultation with a forensic pathologist, and they can be fully subjective, based on 118 clinical history, or other circumstances prior to death, e.g. sudden unexpected death close to vaccination with 119 or without a mention of adverse event. The process needs to be actively initiated and the suspicion can be 120 brought forward by any of the mentioned parties. Usually this happens when death occurs close to 121 vaccination, unexpectedly, or when no other obvious cause of death can be determined based on available 122 clinical data. Threshold for initiating the medicolegal process is kept low especially when a relative 123 expresses the suspicion (23). Finland has one of the highest autopsy rates among high income countries (24),

with medicolegal autopsies carried out in 13.7% during the study period (Table 2; 25), and the overall
autopsy rate being 17.6% of all deaths in 2021 (26).

126 The Finnish Institute for Health and Welfare conducts all medicolegal autopsies in its Forensic Medicine 127 Unit, geographically distributed in five locations covering the whole country. The institute keeps a 128 medicolegal database for all data related to cause-of-death investigation including autopsy reports, death 129 certificates, police reports, and other related documents.

130

131 Individual assessment of causes of death in medicolegal autopsy

132

133 Along with a complete macroscopic examination, each autopsy case includes a routine analysis of

134 histological samples. Most cases also include a toxicological analysis to rule out intoxication, or to assess the

use of alcohol, narcotics, and medications. Based on individual consideration, the forensic pathologist may

136 request further auxiliary investigations, such as neuropathology, microbiological analyses in suspected

137 infections, or serum tryptase level in suspected anaphylaxis (e.g. 27 for further reference).

138 After all relevant investigations, the forensic pathologist determines the most likely *underlying cause of*

139 *death, intermediate causes of death, the immediate cause of death, and contributory causes of death* to be

140 recorded in death certificate.

141 Causes of death, including statements regarding causality, are always approximations based on a case-by-142 case assessment and hence involve uncertainty. In a case of suspected vaccine etiology, currently no exact 143 analysis or procedure exists regarding the COVID-19 vaccines in use, upon which a fatal health condition 144 could definitively be determined as to be caused by a vaccine dose given. When assessing vaccination as a 145 potential etiology for any cause of death, the forensic pathologist should consider several questions 146 including, as suggested by the World Health Organization (28): 1) is there strong evidence for other causes; 147 2) is there a known causal association with the vaccine or vaccination; and 3) was the event within the time 148 window of increased risk? Regarding the second and third questions, one must refer to the current, constantly 149 developing scientific knowledge when determining vaccine as an etiology for any given health condition.

150	Likewise, no exact analysis exists upon which vaccination could with certainty be excluded as an etiology
151	for a given health condition. Notably, a forensic pathologist must largely rely on published data, mostly
152	epidemiologic, when assessing the causal connection between vaccination and death.

154 Selection of medicolegal autopsy cases for further examination

155

156 Data in the medicolegal database are structured and include sex, age, causes of death, the date and location of 157 death, and the personal identification code, which is given to all permanent residents of Finland upon birth or 158 immigration. We examined all medicolegal autopsy cases with both the date of death and the date of autopsy 159 between Dec 26, 2020 (the start of vaccinations in Finland) and Dec 31, 2021 (8,048 autopsy cases). We first 160 excluded cases in which homicide, accident, suicide, or occupational disease was the only grounds for 161 medicolegal autopsy. Then, we also excluded from further evaluation all cases with no mention of having received COVID-19 vaccination in any document recorded in the medicolegal database (police report, 162 163 autopsy referral, any attached patient records, other related documents, or notably also the autopsy report and 164 death certificate). From among the remaining cases in which vaccination was mentioned, one of the 165 researchers, a forensic pathologist (L.P.), determined, whether an actual suspicion of a relationship between 166 vaccination and death had arisen prior to autopsy based on the recorded data. 167 Linkage to vaccinations data and risk factors from the national population-wide registers 168 We linked data between registers and autopsy cases using the personal identification code. We report the sex, 169 age, and vaccination characteristics of the autopsied individuals, along with data from all vaccinated 170 individuals in Finland for comparison. For this purpose, we identified all individuals, whose last known 171 permanent address was in Finland according to the Population Information System, and who received 172 COVID-19 vaccinations according to the Finnish National Vaccination Register between Dec 26, 2020 and 173 Dec 31, 2021 (22). The vaccination register includes the date and vaccine brand of each given COVID-19 174 vaccination.

175 For descriptive purposes, we also linked our cases, along with those COVID-19 vaccinated based on the 176 vaccination register, with data from the care register for health care and the medical reimbursements register 177 on pre-existing risk factors predisposing to severe COVID-19 disease as described in the study of Salo et al. 178 (29). These risk factors, together with age group, were important determinants of the priority and the number 179 of recommended vaccinations for individuals in Finland, and they are also risk factors of death from any 180 cause. These risk factors were: cardiovascular diseases, cognitive disorders, other neurological disorders, 181 diabetes, chronic kidney diseases, chronic liver diseases, pulmonary diseases, immunosuppressive diseases, 182 Addison's disease, schizophrenia, and Down syndrome. Furthermore, data on 24-hour service housing and 183 institutional care were gathered from the same registers. We gathered this risk data starting from Jan 1, 2015 184 until the first vaccine dose, or until death if no record of vaccination was found in the register. Medical 185 reimbursement data was available starting from Jan 1, 2018.

186

187 Ethics

188

189 This descriptive study was conducted as part of the Finnish Institute for Health and Welfare's responsibility 190 to monitor the safety of vaccines used in the national vaccination program and to investigate potential 191 adverse events suspected to be linked with vaccination as dictated by the Finnish law (Act on the National 192 Institute for Health and Welfare 668/2008; Government Decree on the National Institute for Health and 193 Welfare 675/2008; and the Communicable Diseases Act 1227/2016). Based on this, Finnish Institute for 194 Health and Welfare has the statutory right, notwithstanding confidentiality provisions, to access necessary 195 information in cause-of-death investigation documents and to link this information with other relevant 196 register data. Accordingly, this study was approved by the Finnish Institute for Health and Welfare's 197 Director of Health Security department, Director of Government Services department, as well as the Deputy 198 Director General of Research, Development and Innovation. The data on the medicolegal autopsies was 199 originally collected according to the Act on Determining the Cause of Death (459/1973). 200

201 RESULTS

202

203	A total of 428 autopsy cases with a mention of having received COVID-19 vaccination were found, and their
204	records were further investigated for the current report by a forensic pathologist (L.P.). A suspicion of
205	vaccine etiology arose in 76 cases prior to autopsy (Figure). After the autopsy and auxiliary investigations,
206	12 cases emerged, in which the forensic pathologist who wrote the death certificate considered the COVID-
207	19 vaccination as a potential etiological factor for any cause of death: in five cases for the underlying cause
208	of death, and in seven cases for a contributory cause of death (Table 3). Three of these cases had no pre-
209	autopsy suspicion of vaccine etiology, and, thus, were not part of the 76 cases (Figure).
210	Details of the vaccinations preceding death existed in the Vaccination register for 417 cases, including all the
211	12 cases with potential vaccine etiology. In further 4 cases, the medicolegal data included a mention of
212	vaccination with details, and in 7 cases, only a mention of vaccination without any details.
213	Most causes of death with potential vaccine etiology ($n = 12$, see Table 3) were thromboembolic events
214	(7/12) including one VITT with CVST, and one CVST without VITT-association, three cases of pulmonary
215	embolisms, one case of acute myocardial infarction, and one case of recurring cerebral hemorrhage.
216	Furthermore, potential vaccine etiology arose in one case of acute myocarditis, in two cases of diabetic
217	ketoacidosis, in one case of acute pancreatitis, and in one case of eosinophilic granulomatosis with
218	polyangiitis (EGPA). Death occurred within 14 days after vaccination in 7/12 cases. The deaths without a
219	considered vaccine etiology (67/76) were mostly caused by diseases, mainly of cardiovascular origin (Table
220	4).

Prior to autopsy, the suspicion of a relationship between vaccination and death came from treating clinicians in 28 (36.8%) cases, a relative in 24 (31.6%) cases, forensic pathologist in 8 (10.5%) cases, and the police in 1 (1.3%) case (more than one source was possible in each individual case). Twenty-two (28.9%) cases had a mention of a health condition preceding death suspected to be a vaccine-related (mild) adverse reaction, but no actual suspicion of it causing death was stated. Death occurred at home in 48 (63.2%), in a health care unit in 16 (21.1%), in a social welfare unit in 5 (6.6%), and in other places in 7 (9.2%) cases. As regards the 12 cases with potential vaccine etiology, the location of death was home in five cases, health care unit in sixcases, and other in one case.

229 The 12 deaths with potential vaccine etiology occurred in all adult age groups and equally in both sexes 230 (Table 5). Half the cases were autopsied in Helsinki, which has proportionally the most autopsies, and all 231 five autopsy locations had at least one case. Four deaths occurred after each first, second, and third dose, 232 while the number of total administered COVID-19 vaccinations were 4.3, 4.1, and 1.3 million, respectively. 233 Ten of the 12 deaths (83%) occurred after vaccination with BNT162b2, which was the vaccine brand with 234 the largest number of vaccinations administered out of all vaccinations (7.9M / 9.8M; 81%). All 12 cases 235 with potential vaccine etiology had one or more chronic health conditions according to the person level 236 register linkage (Table 3): 7/12 (58%) cases had a record of at least one known pre-existing risk factor, 237 which was a larger proportion than with those vaccinated (1.0M / 4.3M; 23%, Table 5). In 8/12 cases, 238 including the remaining five cases without a register record of risk factors, forensic pathologist determined at 239 least one corresponding chronic condition as one of the causes of death after the autopsy.

240

241 DISCUSSION

242

243 In this nationwide analysis, we searched 8,048 medicolegal autopsy reports comprising all medicolegal 244 autopsies in Finland from Dec 26, 2020 to Dec 31, 2021. For comparison, 58,714 deaths from all causes 245 occurred during this time (Table 2; 25), among which were 952 deaths caused by COVID-19 infection in 246 2021 (30). Moreover, 9.8 million COVID-19 vaccinations were given in Finland, and Finnish Institute for 247 Health and Welfare has estimated that the vaccinations prevented more than 7,300 deaths from COVID-19 248 disease and more than 1,000 deaths with COVID-19 disease as a contributory factor in the country by the 249 end of March, 2022 (31). According to our data, 76 cases included a pre-autopsy suspicion of a relationship 250 between COVID-19 vaccination and death, and, after the autopsy, forensic pathologist considered COVID-251 19 vaccination as a potential etiology for five underlying, and seven contributory causes of death, mainly 252 from thromboembolic causes (7/12). In comparison to the total vaccinated population, the 12 deaths with 253 potential vaccine etiology occurred in both sexes and all adult age groups but included more of those with a third dose and those with known pre-existing risk factors. Due to the remaining uncertainties in catching the right cases, and in considerations about the etiology for the causes of death, the interpretations from the data need to be extremely cautious.

257 To the best of our knowledge, this is the largest published systematic case report series on autopsies 258 conducted in deaths suspected to have COVID-19 vaccine etiology. Most autopsy studies have been single 259 case reports as reviewed by Sessa et al. (16), and a growing number of similar anecdotal reports have been 260 published since. In a Japanese study including 54 cases with death within seven days post vaccination that 261 were autopsied, five cases were concluded to have possible causal relationship between vaccination and 262 death (32). A study from Singapore included 29 autopsy cases from deaths within 72 hours after receiving 263 mRNA-type vaccination, but they did not find any potential causative relationship between vaccination and 264 death in these cases (33). Schneider et al. (34) reported 18 autopsy cases in which death occurred 1-14 days 265 after vaccination in Germany. Of these, five deaths had a potential vaccine etiology including four cases of 266 VITT and one myocarditis (34). Also in Germany, Schwab et al. (35) described 25 autopsy cases with death 267 within 20 days post vaccination, of which five cases died from myocarditis with a potential mRNA-vaccine 268 etiology. Chaves et al. (36) could not find any deaths potentially related to COVID-19 vaccination among the 269 121 autopsies of deceased that had received vaccination in Colombia. In the light of these case series studies, 270 research is needed to reveal to what extent COVID-19 vaccine-related deaths do occur. However, no 271 conclusions can be made on the frequency of potential vaccine-related deaths based on autopsy-studies 272 alone, as the selection criteria for autopsy differ between studies and, more importantly, between countries. 273 In seven of the twelve deaths in our data, forensic pathologist writing the death certificate considered 274 COVID-19 vaccination a potential etiological factor for a diagnosed thromboembolism, which were also the 275 most frequent causes of death considered vaccine-related in previous reports (16). Among these seven cases, 276 only one case of VITT with CVST was identified. Another CVST without thrombocytopenia was also 277 detected. Due to the relatively early cessation of vaccination with ChAdOx1, exposure to this vaccine brand 278 was a minority in Finland (Table 5), which may have limited the occurrence of these potentially lethal 279 adverse reactions. The estimated cumulative 28-day-incidence of VITT has been between 1/26,500 and 280 1/1,000,000 first doses of ChAdOx1 with lower incidences for subsequent doses (5, 37–38). According to

281 See et al. (39), the incidence of VITT after vaccination with Ad26.COV2.S was 1/583,000 doses. The 282 estimated incidence for VITT with CVST after receiving the first dose of ChAdOx1 was 12.3 / 1,000,000 283 when the condition was first recognized as an adverse reaction (40). The rate is clearly higher than the 284 background cumulative 28-day incidence of 0.18 / 1,000,000 (41). Mortality caused by VITT in the 285 COVID-19 vaccinated is unknown, but it is thought to be extremely low (37). However, among patients with 286 diagnosed VITT, the mortality rates have varied 23–73% (5), though with early recognition and adequate 287 care, the prognosis has improved (42). Post vaccination CVST can occur with or without the context of 288 VITT, but with significantly better outcomes, when no thrombocytopenia-association is present (40, 43). 289 Of the seven cases with thromboembolism, three deaths were from pulmonary embolisms, one death from 290 acute myocardial infarction, and one death from recurring cerebral hemorrhage. Deep vein thrombosis and 291 pulmonary embolism are common entities, and the latter is frequently the cause of sudden death in the 292 medicolegal context. Case reports of post vaccination pulmonary embolisms have been published (44), but 293 further population-based studies on ChAdOx (45), and BNT162b2 (46) found no evidence of any increased 294 incidence of pulmonary embolisms after vaccination. However, in a self-controlled case series study in the 295 French population, a slight increase in risk for pulmonary embolism was associated with the first dose of 296 ChAdOx1 (relative incidence 1.41, confidence interval 1.13–1.75) but not with BNT162b2 or mRNA-1273 297 (47). Myocardial infarctions and other acute cardiovascular events are common manifestations in the general 298 population, and they occur after vaccination as well. It has been suggested that COVID-19 vaccination could 299 contribute to cardiovascular events through enhancing prothrombotic state or, unspecifically, as a stress 300 factor (48). As with pulmonary embolism, Botton et al. (47) found an increase in the risk for myocardial 301 infarction after the first dose of ChAdOx1 (relative incidence 1.29, confidence interval 1.11–1.51), and after 302 Ad26.COV2.S (relative incidence 1.75, confidence interval 1.16–2.62), but not with the mRNA-type 303 vaccines. Again, no increased risk for myocardial infarction arose in connection with BNT162b2 in other 304 large study settings as reviewed by Yong et al. (49). Hence, although COVID-19 vaccination was, according 305 to the medicolegal assessment, considered a potential etiological factor for pulmonary embolism in three of 306 our cases and myocardial infarction in one case, all vaccinated with BNT162b2, we found no 307 epidemiological evidence to support these decisions.

308 One case of post vaccination fatal acute myocarditis with potential vaccine etiology was present in our study 309 population in the age group 35 to 64 years. A link between myocarditis and mRNA-type COVID-19 vaccines 310 has been established in large cohort studies (10-11). The highest risk for developing myocarditis has 311 occurred in young men after receiving the second dose (50) Case reports of vaccination-associated 312 myocarditis deaths have been published (35, 51), but, in large study settings, post vaccination myocarditis 313 has rarely been associated with death (8, 10, 13, 50, 52). Notably, myocardial injury associated with a 314 clinical diagnosis of myocarditis after COVID-19 vaccination has been reported mild, as reviewed by Garg 315 et al. (53). In the present study, forensic pathologist considered COVID-19 vaccination as contributory cause 316 of death in two cases with type 1 diabetes mellitus and diabetic ketoacidosis. In one of them, the vaccine was 317 a potential etiological factor for the onset of diabetes, and in the other, it potentially contributed to the 318 worsening of glucose balance in a patient with previously diagnosed diabetes. Many case reports and case 319 series have been published describing post vaccination hyperglycemia, hyperosmolar hyperglycemic 320 syndrome, and diabetic ketoacidosis regardless of the COVID-19 vaccine type as reviewed by Samuel et al. 321 (54). However, we could find only one self-controlled case series analysis regarding acute diabetic 322 complications in patients with type 2 diabetes receiving BNT162b2 (55). According to the study of Wan et 323 al. (55), no ketoacidoses emerged among the 141,224 cases given BNT162b2, and no increased risk for other 324 diabetic complications was observed, either. We did not find any large-scale studies about the effects of 325 COVID-19 vaccines on the onset or on the clinical picture of type 1 diabetes. These kinds of epidemiological 326 studies are warranted, as in some case studies, COVID-19 vaccines were suggested to play a role in the onset 327 of autoimmune diseases, including type 1 diabetes (as reviewed by Chen et al. (56)). 328 Herein, one case of fatal acute pancreatitis emerged with COVID-19 vaccination as its potential etiology. A 329

few case reports about non-fatal post vaccination pancreatitis have been published, mainly concerning

BNT162b2 (e.g., 57–58), but we did not find any epidemiological studies addressing the potential

association of vaccination and pancreatitis. Lastly, we had one autopsy case who had EGPA, a small-vessel

- vasculitis, determined as the underlying cause of death, and COVID-19 vaccine considered as potential
- etiology for the disease. As with pancreatitis, only a few case reports of new onset or relapse of EGPA after
- 334 COVID-19 vaccination have been published, all regarding mRNA vaccines (59–62). Our findings suggest

that further research on the relationship between COVID-19 vaccination and both acute pancreatitis andEGPA is warranted.

337 As we have described in the methods, determining as well as excluding vaccination as an etiology for any 338 cause of death involves a lot of uncertainty, and should be based on epidemiological evidence of association 339 between the vaccination and the adverse event which contributed to the fatality (28). Also, it must be stressed 340 that we only examined the outcomes of the cause-of-death investigation as done by each individual forensic 341 pathologist, and, as such, we did not re-evaluate the possibility of vaccine-etiology in any of the cases. The 342 medicolegal cause-of-death investigation process comprises of gathering information regarding patient 343 history (known diseases, possible symptoms, and findings prior to death) and other circumstances preceding 344 death, as well as examining data received from the autopsy and auxiliary investigations. Based on these, the 345 forensic pathologist generates a most likely scenario including the causes of death and the potential 346 etiologies involved. This scenario is then presented in the autopsy report along with discussion of the 347 uncertainties in each case. It is possible that true vaccine-related deaths were missed, and some of these may 348 even be among the 67 cases in which the forensic pathologist did not consider vaccination as potential 349 etiology. Notably, among these were nine acute myocardial infarctions, five pulmonary embolisms, and one 350 case in which the causes of death could not be determined. However, the lack of epidemiological support 351 (47, 49), and the fact that more plausible etiologies were present (e.g. malignancy in case of pulmonary 352 embolism) argue against a significant proportion of true vaccine-related deaths in our study. 353 Death occurred within 30 days of last vaccination in ten of the twelve cases with vaccination considered as 354 an etiology for a cause of death. We did not examine the interval between vaccination and death in all 355 included autopsies, as some authors have done (32-33, 35. All-cause mortality following COVID-19

356 vaccination has been studied on population level in Finland, and the hazard of death did not increase within

63 days of COVID-19 vaccination in Finland (63). Also, a meta-analysis including three self-controlled case
series studies totaling 750,000 patients found no association between COVID-19 vaccination and all-cause
mortality (64).

Because the initiation of the medicolegal process in a suspected vaccine-related death is dependent on a
suspicion being brought up, not all cases end up in the hands of forensic pathologist, as seen in the context of

iatrogenic deaths (65). This can more often be the case in deaths among elderly people with several chronic
illnesses than in deaths deemed more unexpected, as is evident when comparing the medicolegal autopsy
rates between 18-34-year-olds (82%) and 65-year-olds and older (9%).

365 Prior to autopsy, the suspicion of the role of COVID-19 vaccine in death was brought forward mostly by

treating clinicians. Health care personnel are in a key position in spotting potential iatrogenic deaths, and

they are required by law to report such cases to the police in Finland. The systems of investigating suspected

iatrogenic deaths differ greatly between countries (66) depending partly on whether it is looked at from the

369 viewpoint of clinical risk management, or whether actual malpractice claims have been raised (23).

370 In many cases, the suspicion of a relationship between COVID-19 vaccine and death was also expressed by

the deceased's next of kin, which is in line with today's growing numbers of medical malpractice issues (67).

372 COVID-19 vaccinations have been the topic of extensive public discussions globally, and views

discouraging against vaccination on account of alleged hazards have occasionally gained ground (14).

374 Because of this, it is essential to investigate all suspected COVID-19 vaccine-related deaths thoroughly and

375 openly to address these concerns and, if so indicated, maintain the public's confidence in vaccinations.

376

377 Conclusions

378 In the context of total vaccinated population and of the number of given vaccine doses, only a few suspicions 379 of vaccine-related deaths arose in the first year of COVID-19 vaccinations in Finland. Even fewer were the 380 number of deaths, in which the forensic pathologist performing the cause-of-death investigation considered 381 vaccine as a potential etiological factor for a cause of death. Although autopsy is a crucial tool in 382 determining the causes of death through detection and documentation of tissue reactions, other settings, such 383 as large epidemiological studies, should be performed to support individual case-assessment. Our study 384 highlights the need for further research related to diabetes, acute pancreatitis and EGPA as potential serious 385 adverse reactions of COVID-19 vaccines. Also, deaths associated with thromboembolic events and 386 myocarditis after vaccination need closer examination. A continuing evaluation of suspected COVID-19 387 vaccine-related deaths is essential in monitoring vaccination safety.

389	ACKNOWLEDGEMENTS		
390	The authors are grateful to the supporting staff of the Forensic Medicine Unit in gathering data. This study		
391	received no specific funding.		
392			
393	REFEI	RENCES	
394	1.	Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19	
395		vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-260. doi:	
396		10.1016/j.ijid.2021.11.009.	
397			
398	2.	World Health Organization. Covid-19 vaccines: Safety surveillance manual, second edition. Geneva:	
399		World Health Organization 2021.	
400			
401	3.	European Medicine Agency. Guideline on good pharmacovigilance practices (GVP), Annex I -	
402		Definitions (Rev 4). https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-	
403		pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf. Accessed 21/04/2023.	
404			
405	4.	European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very	
406		rare cases of unusual blood clots with low blood platelets.	
407		https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-	
408		rare-cases-unusual-blood-clots-low-blood. Accessed 28/01/2023.	
409			
410	5.	Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia.	
411		Lancet Haematol. 2022;9(1):e73-e80. doi: 10.1016/S2352-3026(21)00306-9.	
412			

413	6.	European Medicines Agency. EMA raises awareness of clinical care recommendations to manage
414		suspected thrombosis with thrombocytopenia syndrome. https://www.ema.europa.eu/en/news/ema-
415		raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia.
416		Accessed 15/03/2023.
417		
418	7.	Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A.
419		Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post
420		COVID-19 vaccination; a systematic review. J Neurol Sci. 2021;428:117607. doi:
421		10.1016/j.jns.2021.117607.
422		
423	8.	Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation
424		2021;144(6):471-484. doi: 10.1161/CIRCULATIONAHA.121.056135.
425		
426	9.	Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, Sørensen HT, Andersen
427		M, Wohlfahrt J, Gislason G, Torp-Pedersen C, Køber L, Hviid A. SARS-CoV-2 vaccination and
428		myocarditis or myopericarditis: population based cohort study. BMJ 2021;375:e068665. doi:
429		10.1136/bmj-2021-068665.
430		
431	10.	Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, Hansen JV, Nohynek H,
432		Gunnes N, Sundström A, Wohlfahrt J, Nieminen TA, Grünewald M, Gulseth HL, Hviid A, Ljung R.
433		SARS-CoV-2 Vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA
434		Cardiol. 2022;7(6):600-612. doi: 10.1001/jamacardio.2022.0583.
435		
436	11.	Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM,
437		Schlaudecker E, Lang SM, Barnett ED, Ruberg FL, Smith MJ, Campbell MJ, Lopes RD, Sperling
438		LS, Baumblatt JA, Thompson DL, Marquez PL, Strid P, Woo J, Pugsley R, Reagan-Steiner S,
439		DeStefano F, Shimabukuro TT. Myocarditis cases reported after mRNA-based COVID-19

440	vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331-340. doi:
441	10.1001/jama.2021.24110.
442	
443	12. Husby A, Køber L. COVID-19 mRNA vaccination and myocarditis or pericarditis. Lancet.
444	2022;399(10342):2168-2169. doi: 10.1016/S0140-6736(22)00842-X.
445	
446	13. Husby A, Gulseth HL, Hovi P, Hansen JV, Pihlström N, Gunnes N, Härkänen T, Dahl J, Karlstad Ø,
447	Heliö T, Køber L, Ljung R, Hviid A. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA
448	vaccination in four Nordic countries: population based cohort study. BMJ Medicine 2023;2:e000373.
449	doi: 10.1136/bmjmed-2022-000373.
450	
451	14. Pullan S, Dey M. Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google
452	Trends analysis. Vaccine. 2021;39(14):1877–1881. doi: 10.1016/j.vaccine.2021.03.019.
453	
454	15. Gisondi MA, Barber R, Faust JS, Raja A, Strehlow MC, Westafer LM, Gottlieb M. A deadly
455	infodemic: social media and the power of COVID-19 misinformation. J Med Internet Res.
456	2022;24(2):e35552. doi: 10.2196/35552.
457	
458	16. Sessa F, Salerno M, Esposito M, Di Nunno N, Zamboni P, Pomara C. Autopsy findings and
459	causality relationship between death and COVID-19 vaccination: a systematic review. J Clin Med.
460	2021;10(24):5876. doi: 10.3390/jcm10245876.
461	
462	17. European Centre for Disease Prevention and Control. COVID-19 vaccine tracker.
463	https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#summary-
464	tab. Accessed 28/01/2023.
465	
466	18. Finnish Institute for Health and Welfare. COVID-19 vaccinations in Finland.
467	https://sampo.thl.fi/pivot/prod/en/vaccreg/cov19cov/fact_cov19cov?&row=cov_vac_dose-

468		533170.533164.639082.&row=area-
469		518327.518294.518309.518306.518320.518377.518303.518340.518369.518295.518335.518322.518
470		353.518298.518343.518354.518351.518300.518366.518323.518349.518362.&column=cov_vac_ag
471		e-518413&column=660963L&filter=measure-533185. Accessed 28/01/2023.
472		
473	19.	. Finnish Institute for Health and Welfare. Arranging COVID-19 vaccinations in Finland.
474		https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-
475		updates/vaccines-and-coronavirus/arranging-covid-19-vaccinations-in-finland. Accessed
476		28/01/2023.
477		
478	20.	. Finnish Institute for Health and Welfare. Koronarokotusten järjestäminen Suomessa [Finnish].
479		https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista/ajankohtaista-koronavirukset/ajankohtaista/ajankohtaista-koronavirukset/ajankohtaista-koronavirukset/ajankohtaista/ajankohtaista/ajankohtaista-koronavirukset/ajankohtaista-koronavirukset/ajankohtaista/ajankohtaista/ajankohtaista-koronavirukset/ajankohtaista/ajankohtaista-koronavirukset/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtaista/ajankohtai
480		19/rokotteet-ja-koronavirus/koronarokotusten-jarjestaminen-suomessa. Accessed 16/02/2023.
481		
482	21.	. Finnish Institute for Health and Welfare. THL issues instructions that men under 30 years of age
483		should only be offered the Comirnaty coronavirus vaccine. https://thl.fi/en/web/thlfi-en/-/thl-issues-
484		instructions-that-men-under-30-years-of-age-should-only-be-offered-the-comirnaty-coronavirus-
485		vaccine. Accessed 28/01/2023.
486		
487	22.	. Baum U, Sundman J, Jääskeläinen S, Nohynek H, Puumalainen T, Jokinen J. Establishing and
488		maintaining the National Vaccination Register in Finland. Euro Surveill. 2017;22(17):30520. doi:
489		10.2807/1560-7917.ES.2017.22.17.30520.
490		
491	23.	. Pakanen L, Keinänen N, Kuvaja P. Presumed adverse events in health care are a frequent indication
492		for medico-legal autopsy in Finland. Forensic Sci Med Pathol. 2020;16(1):65-70. doi:
493		10.1007/s12024-019-00193-4.
494		

495	24	. Lunetta P, Lounamaa A, Sihvonen S. Surveillance of injury-related deaths: medicolegal autopsy
496		rates and trends in Finland. Inj Prev. 2007;13(4):282-4. doi: 10.1136/ip.2006.012922.
497		
498	25	. Official Statistics of Finland. Deaths. ISSN=1798-2545. Helsinki: Statistics Finland.
499		
500	26	Statistics Finland. 11c1 Autopsies and other means to determine cause of death by age and sex of
501		deceased, 1975–2021.
502		https://pxdata.stat.fi/PxWeb/pxweb/en/StatFin/StatFin_ksyyt/statfin_ksyyt_pxt_11c1.px/. Accessed
503		28/01/2023.m
504		
505	27	. Madea B, ed. Handbook of forensic medicine. Wiley-Blackwell: Hoboken, NJ. 2014.
506		
507	28	. World Health Organization. Causality assessment of an adverse event following immunization
508		(AEFI): user manual for the revised WHO classification, 2nd ed. World Health Organization,
509		Geneva, Switzerland. https://apps.who.int/iris/handle/10665/259959. Accessed 28/01/2023.
510		
511	29	. Salo H, Lehtonen T, Auranen K, Baum U, Leino T. Predictors of hospitalisation and death due to
512		SARS-CoV-2 infection in Finland: A population-based register study with implications to
513		vaccinations. Vaccine. 2022;40(24):3345-3355. doi: 10.1016/j.vaccine.2022.04.055.
514		
515	30	. Statistics Finland. Causes of death. Reference period: 2021. Helsinki: Statistics Finland.
516		https://www.stat.fi/en/publication/cktdxrx6o4sv90b62jy6t7qbg. Accessed 28/01/2023.
517		
518	31	. Finnish Institute for Health and Welfare. Study: Coronavirus vaccines prevented around 7,300
519		deaths due to COVID-19 in Finland by the end of March 2022. https://thl.fi/en/web/thlfi-en/-/study-
520		coronavirus-vaccines-prevented-around-7-300-deaths-due-to-covid-19-in-finland-by-the-end-of-
521		march-2022. Accessed 28/01/2023.
522		

523	32.	Suzuki H, Ro A, Takada A, Saito K, Hayashi K. Autopsy findings of post-COVID-19 vaccination
524		deaths in Tokyo Metropolis, Japan, 2021. Leg Med. 2022;59:102134. doi:
525		10.1016/j.legalmed.2022.102134.
526		
527	33.	Yeo A, Kuek B, Lau M, Tan SR, Chan S. Post COVID-19 vaccine deaths - Singapore's early
528		experience. Forensic Sci Int. 2022;332:111199. doi: 10.1016/j.forsciint.2022.111199.
529		
530	34.	Schneider J, Sottmann L, Greinacher A, Hagen M, Kasper H-U, Kuhnen C, Schlepper S, Schmidt S,
531		Schulz R, Thiele T, Thomas C, Schmeling A. Postmortem investigation of fatalities following
532		vaccination with COVID-19 vaccines. Int J Legal Med. 2021;135(6):2335-2345. doi:
533		10.1007/s00414-021-02706-9.
534		
535	35.	Schwab C, Domke LM, Hartmann L, Stenzinger A, Longerich T, Schirmacher P. Autopsy-based
536		histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. Clin Res
537		Cardiol. 2023;112(3):431-440. doi: 10.1007/s00392-022-02129-5.
538		
539	36.	Chaves JJ, Bonilla JC, Chaves-Cabezas V, Castro A, Polo JF, Mendoza O, Correa-Rodríguez J,
540		Piedrahita AC, Romero-Fandiño IA, Caro MV, González AC, Sánchez LK, Murcia F, Márquez G,
541		Benavides A, Quiroga MDP, López J, Parra-Medina R. A postmortem study of patients vaccinated
542		for SARS-CoV-2 in Colombia. Rev Esp Patol. 2023;56(1):4–9. doi: 10.1016/j.patol.2022.09.003.
543		
544	37.	Aleem A, Nadeem AJ. Coronavirus (COVID-19) vaccine-induced immune thrombotic
545		thrombocytopenia (VITT). 2. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island, FL.
546		2022.
547		
548	38.	Pai M. Epidemiology of VITT. Semin Hematol. 2022;59(2):72–75. doi:
549		10.1053/j.seminhemato1.2022.02.002.
550		

551	39.	See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP,
552		Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT,
553		Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. US case reports
554		of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March
555		2 to April 21, 2021. JAMA. 2021;325(24):2448-2456. doi: 10.1001/jama.2021.7517.
556		
557	40.	Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, Yeo JM, Zhang L,
558		Hassan-Smith G, Jones M, Hutchcroft C, Hobson E, Warcel D, White D, Ferdinand P, Webb A,
559		Solomon T, Scully M, Werring DJ, Roffe C, CVT After Immunisation Against COVID-19 (CAIAC)
560		collaborators. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a
561		multicentre cohort study. Lancet. 2021;398(10306):1147-1156. doi: 10.1016/S0140-6736(21)01608-
562		1.
563		
564	41.	Hovi P, Palmu AA, Nieminen TA, Artama M, Jokinen J, Ruokokoski E, Lassila R, Nohynek H,
565		Kilpi T. Incidence of sinus thrombosis with thrombocytopenia-A nation-wide register study. PLoS
566		One. 2023;18(2):e0282226. doi: 10.1371/journal.pone.0282226.
567		
568	42.	van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sánchez van Kammen M, Heldner MR, Jood
569		K, Lindgren E, Tatlisumak T, Putaala J, Kremer Hovinga JA, Middeldorp S, Levi M, Arnold M,
570		Ferro JM, Coutinho JM. Declining mortality of cerebral venous sinus thrombosis with
571		thrombocytopenia after SARS-CoV-2 vaccination. Eur J Neurol. 2022;29(1):339-344. doi:
572		10.1111/ene.15113.
573		
574	43.	Sánchez van Kammen M, Aguiar de Sousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof
575		A, Krzywicka K, van Haaps T, Ciccone A, Middeldorp S, Levi MM, Kremer Hovinga JA, Silvis S,
576		Hiltunen S, Mansour M, Arauz A, Barboza MA, Field TS, Tsivgoulis G, Nagel S, Lindgren E,
577		Tatlisumak T, Jood K, Putaala J, Ferro JM, Arnold M, Coutinho JM; Cerebral Venous Sinus
578		Thrombosis With Thrombocytopenia Syndrome Study Group; Sharma AR, Elkady A, Negro A,

579	Günther A, Gutschalk A, Schönenberger S, Buture A, Murphy S, Paiva Nunes A, Tiede A,
580	Puthuppallil Philip A, Mengel A, Medina A, Hellström Vogel Å, Tawa A, Aujayeb A, Casolla B,
581	Buck B, Zanferrari C, Garcia-Esperon C, Vayne C, Legault C, Pfrepper C, Tracol C, Soriano C,
582	Guisado-Alonso D, Bougon D, Zimatore DS, Michalski D, Blacquiere D, Johansson E, Cuadrado-
583	Godia E, De Maistre E, Carrera E, Vuillier F, Bonneville F, Giammello F, Bode FJ, Zimmerman J,
584	d'Onofrio F, Grillo F, Cotton F, Caparros F, Puy L, Maier F, Gulli G, Frisullo G, Polkinghorne G,
585	Franchineau G, Cangür H, Katzberg H, Sibon I, Baharoglu I, Brar J, Payen JF, Burrow J, Fernandes
586	J, Schouten J, Althaus K, Garambois K, Derex L, Humbertjean L, Lebrato Hernandez L, Kellermair
587	L, Morin Martin M, Petruzzellis M, Cotelli M, Dubois MC, Carvalho M, Wittstock M, Miranda M,
588	Skjelland M, Bandettini di Poggio M, Scholz MJ, Raposo N, Kahnis R, Kruyt N, Huet O, Sharma P,
589	Candelaresi P, Reiner P, Vieira R, Acampora R, Kern R, Leker R, Coutts S, Bal S, Sharma SS,
590	Susen S, Cox T, Geeraerts T, Gattringer T, Bartsch T, Kleinig TJ, Dizonno V, Arslan Y.
591	Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2
592	vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 2021;78(11):1314–1323.
593	doi: 10.1001/jamaneurol.2021.3619.
593 594	doi: 10.1001/jamaneurol.2021.3619.
	doi: 10.1001/jamaneurol.2021.3619. 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary
594	
594 595	44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary
594 595 596	44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary
594 595 596 597	44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877–
594 595 596 597 598	44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877–
594 595 596 597 598 599	 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877–879. doi: 10.1080/20009666.2021.1990825.
594 595 596 597 598 599 600	 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877– 879. doi: 10.1080/20009666.2021.1990825. 45. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and
594 595 596 597 598 599 600 601	 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877– 879. doi: 10.1080/20009666.2021.1990825. 45. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet.
594 595 596 597 598 599 600 601 602	 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877– 879. doi: 10.1080/20009666.2021.1990825. 45. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet.
594 595 596 597 598 599 600 601 602 603	 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up. J Community Hosp Intern Med Perspect. 2021;11(6):877–879. doi: 10.1080/20009666.2021.1990825. 45. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021;397(10283):1441–1443. doi: 10.1016/S0140-6736(21)00762-5.

608	47. Botton J, Jabagi MJ, Bertrand M, Baricault B, Drouin J, Le Vu S, Weill A, Farrington P, Zureik M,
609	Dray-Spira R. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-
610	19 vaccines in adults younger than 75 years in France. Ann Intern Med. 2022;175(9):1250-1257.
611	doi: 10.7326/M22-0988.
612	
613	48. Aye YN, Mai AS, Zhang A, Lim OZH, Lin N, Ng CH, Chan MY, Yip J, Loh PH, Chew NWS.
614	Acute myocardial infarction and myocarditis following COVID-19 vaccination. QJM.
615	2021;hcab252. doi: 10.1093/qjmed/hcab252.
616	
617	49. Yong SJ, Halim A, Halim M, Al Mutair A, Alhumaid S, Al-Sihati J, Albayat H, Alsaeed M, Garout
618	M, Al Azmi R, Aldakheel N, Alshukairi AN, Al Ali HA, Almoumen AA, Rabaan AA. Rare adverse
619	events associated with BNT162b2 mRNA vaccine (Pfizer-BioNTech): a review of large-scale,
620	controlled surveillance studies. Vaccines. 2022;10(7):1067. doi: 10.3390/vaccines10071067.
621	
622	50. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T,
623	Levi N, Asleh R, Amir O, Meir K, Cohen D, Dichtiar R, Novick D, Hershkovitz Y, Dagan R,
624	Leitersdorf I, Ben-Ami R, Miskin I, Saliba W, Muhsen K, Levi Y, Green MS, Keinan-Boker L,
625	Alroy-Preis S. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J
626	Med. 2021;385(23):2140-2149. doi: 10.1056/NEJMoa2109730.
627	
628	51. Choi S, Lee S, Seo J-W, Kim M-J, Jeon YH, Park JH, Lee JK, Yeo NS. Myocarditis-induced Sudden
629	Death after BNT162b2 mRNA COVID-19 vaccination in Korea: Case report focusing on
630	histopathological findings. J Korean Med Sci. 2021 Oct 18;36(40):e286. doi:
631	10.3346/jkms.2021.36.e286.
632	
633	52. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K,
634	Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. Risks of

635	myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-
636	CoV-2 infection. Nat Med. 2022;28(2):410-422. doi: 10.1038/s41591-021-01630-0.
637	
638	53. Garg R, Hussain M, Friedrich MG. Phenotyping myocardial injury related to COVID and SARS-
639	CoV-2 vaccination: insights from cardiovascular magnetic resonance. Front Cardiovasc Med.
640	2023;10:1186556. doi: 10.3389/fcvm.2023.1186556.
641	
642	54. Samuel SM, Varghese E, Triggle CR, Büsselberg D. COVID-19 vaccines and hyperglycemia-is
643	there a need for postvaccination surveillance? Vaccines. 2022;10(3):454. doi:
644	10.3390/vaccines10030454.
645	
646	55. Wan EYF, Chui CSL, Mok AHY, Xu W, Yan VKC, Lai FTT, Li X, Wong CKH, Chan EWY, Lui
647	DTW, Tan KCB, Hung IFN, Lam CLK, Leung GM, Wong ICK. mRNA (BNT162b2) and
648	inactivated (CoronaVac) COVID-19 vaccination and risk of adverse events and acute diabetic
649	complications in patients with type 2 diabetes mellitus: a population-based study. Drug Saf.
650	2022;45(12):1477–1490. doi: 10.1007/s40264-022-01228-6.
651	
652	56. Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, Pan HF. New-onset autoimmune phenomena
653	post-COVID-19 vaccination. Immunology. 2022;165(4):386-401. doi: 10.1111/imm.13443.
654	
655	57. Cacdac R, Jamali A, Jamali R, Nemovi K, Vosoughi K, Bayraktutar Z. Acute pancreatitis as an
656	adverse effect of COVID-19 vaccination. SAGE Open Med Case Rep.
657	2022;10:2050313X221131169. doi: 10.1177/2050313X221131169.
658	
659	58. Kalra RK, Jayadeep S, Ball AL. Acute pancreatitis in an adolescent following COVID vaccination.
660	Clin Pediatr. 2022;61(3):236–240. doi: 10.1177/00099228211067678.
661	

662	59. Costanzo G, Ledda AG, Ghisu A, Vacca M, Firinu D, Del Giacco S. Eosinophilic granulomatosis
663	with polyangiitis relapse after COVID-19 vaccination: a case report. Vaccines. 2021;10(1):13. doi:
664	10.3390/vaccines10010013.
665	
666	60. Chan-Chung C, Ong CS, Chan LL, Tan EK. Eosinophilic granulomatosis with polyangiitis after
667	COVID-19 vaccination. QJM. 2022;114(11):807-809. doi: 10.1093/qjmed/hcab273.
668	
669	61. Ibrahim H, Alkhatib A, Meysami A. Eosinophilic granulomatosis with polyangiitis diagnosed in an
670	elderly female after the second dose of mRNA vaccine against COVID-19. Cureus.
671	2022;14(1):e21176. doi: 10.7759/cureus.21176.
672	
673	62. Nappi E, De Santis M, Paoletti G, Pelaia C, Terenghi F, Pini D, Ciccarelli M, Selmi CF, Puggioni F,
674	Canonica GW, Heffler E. New onset of eosinophilic granulomatosis with polyangiitis following
675	mRNA-based COVID-19 vaccine. Vaccines. 2022;10(5):716. doi: 10.3390/vaccines10050716.
676	
677	63. Nieminen T, Hovi P, Härkänen T, Kaukonen M, Nohynek H. Kuolleisuus välittömästi
678	koronarokottamisen jälkeen : Koronarokotusten turvallisuus Suomessa [Finnish] [Hazard of death
679	immediately following COVID-19 vaccination]. Finnish Institute for Health and Welfare (THL),
680	Helsinki, Finland. https://urn.fi/URN:ISBN:978-952-343-981-8. Accessed 15/09/2023.
681	
682	64. Marchand G, Masoud AT, Medi S. Risk of all-cause and cardiac-related mortality after vaccination
683	against COVID-19: A meta-analysis of self-controlled case series studies. Hum Vaccin Immunother
684	2023;19(2):2230828. doi: 10.1080/21645515.2023.2230828.
685	
686	65. Kuvaja P, Keinänen N, Pakanen L. The incidence of iatrogenic deaths in the Finnish cause-of-death
687	statistics; a retrospective study. J Forensic Leg Med. 2022 Feb;86:102302. doi:
688	10.1016/j.jflm.2021.102302.
689	

690	66. Ferrara SD, Baccino E, Bajanowski T, Boscolo-Berto R, Castellano M, De Angel R, Pauliukevičius
691	A, Ricci P, Vanezis P, Vieira DN, Viel G, Villanueva E; EALM Working Group on Medical
692	Malpractice. Malpractice and medical liability. European guidelines on methods of ascertainment
693	and criteria of evaluation. Int J Legal Med. 2013;127(3):545–557. doi: 10.1007/s00414-013-0836-5.
694	
695	67. Ferrara SD. Medical malpractice and legal medicine. Int J Legal Med. 2013;127(3):541–543. doi:
696	10.1007/s00414-013-0839-2.
697	
698	
699	
700	FIGURE LEGENDS
701	
702	Figure. Flow chart presenting the selection of autopsy cases. Vaccination data was obtained from Finnish
703	National Vaccination Register.
704	
705	CONFLICT OF INTEREST
706	L.P. is a former small shareholder of AstraZeneca. H.N. is a member of the National Immunization
707	Technical Advisory Group of Finnish Institute for Health and Welfare (THL). H.N. is chair of the WHO
708	Strategic Advisory Group of Experts. THL has until 9/2022 conducted Public-Private Partnerships with
709	vaccine manufacturers and has previously received research funding for studies unrelated to COVID-19 from
710	GlaxoSmithKline Vaccines, Pfizer, and Sanofi Pasteur (including T.N. as an investigator). All other authors
711	declare no financial or non-financial competing interests.
712	

TABLES

715 Table 1. Definitions of vaccine-related incidents used in this paper.

Term	Definition
Adverse event following immunization (AEFI)	Any health condition or problem that occurs
	following immunization and which does not
	necessarily have a causal relationship with
	vaccination (3)
(Serious) adverse reaction	Noxious and unintended health condition in
	response to vaccination with a suspected causal
	relationship. Serious adverse reactions include
	health conditions which are life-threatening or
	result in death (3).
Unrelated health problems following vaccination	Health condition considered not to be caused by
	vaccine
Cause of death	Cause of death as stated in the death certificate
	determined by a forensic pathologist or another
	physician

719 Table 2. Medicolegal autopsies carried out in relation to total death during the study period, Dec 26,

2020 – Dec 31, 2021.

	Medicolegal autopsies	Total deaths (25)	Autopsy-percentage
End of follow-up	Dec 31, 2021	Dec 31, 2021	
Number of cases	8,048	58,714	13.7
Sex			
Men	5,597	29,697	18.9
Women	2,451	29,017	8.5
Age, years			
< 18	80	214	37.4
18–34	531	646	82.2
35–64	2,751	6,862	40.1
≥ 65	4,686	50,992	9.2

- 722 Table 3. Details of all cases in Finland in which a forensic pathologist considered a cause of death to
- 723 have COVID-19 vaccine etiology.

Cause of death	Brand of	Days between	Age	Predisposing risk	Other causes of death ¹
considered to have	last	vaccination	group	factors (register	
vaccine etiology ¹	vaccine	and death ²		data) ³	
	dose				
VITT with CVST	ChAdOx1	11	35–64	Diabetes,	-
(U)				neurological	
				condition	
CVST without	BNT162b2	40	18–34	-	Coagulation disorder
VITT-association					(C), morbid obesity (C)
(U)					
Acute myocarditis	BNT162b2	4	35–64	-	Coronary artery disease
(U)					(C), alcohol use (C)
Acute pancreatitis	BNT162b2	3	35–64	Cardiovascular	-
(U)				disease,	
				immunosuppressive	
				diseases,	
				pulmonary diseases	
Contribution to	BNT162b2	10	≥65	Cardiovascular	Cognitive disorder (U),
pulmonary				diseases, Cognitive	pneumonia (I), coronary
embolism (C)				disorders, 24-hour	artery disease (C),
				service housing	sequelae of cerebral
					infarction (C),
					pulmonary embolism
					(C)
Contribution to	BNT162b2	24	≥65	Cardiovascular	Pulmonary embolism

pulmonary				disease	(U)
embolism (C)					
Contribution to	BNT162b2	27	≥65	Immunosuppressiv	Myocardial hypertrophy
pulmonary				e diseases	(U), deep vein
embolism (C)					thrombosis (INT),
					pulmonary embolism (I)
Eosinophilic	BNT162b2	170 ²	35–64	Pulmonary diseases	Pulmonary embolism (I)
granulomatosis					
with polyangiitis					
(U)					
Worsening of	ChAdOx1	6	35–64	Diabetes,	Type 1 diabetes (U),
glucose balance,				immunosuppressive	coronary artery disease
ketoacidosis (C)				diseases, Addison's	(C)
				disease	
Onset of diabetes,	BNT162b2	17	18–34	-	Type 1 diabetes (U),
ketoacidosis (C)					cerebral oedema (I),
					pneumonia (C)
Contribution to	BNT162b2	12	≥65	-	Cerebral amyloid
recurring cerebral					angiopathy (U),
hemorrhage (C)					intracerebral
					hemorrhage (INT),
					pneumonia (I)
Contribution to	BNT162b2	9	≥65	-	Coronary artery disease
myocardial					(U), myocardial
infarction (C)					infarction (I)

724 ¹Cause of death was U = underlying, INT = intermediate, I = immediate, or C = contributory.

- ²Note that this is the delay from vaccination to death. The delay from vaccination to onset of the health
- condition is not included in the research data.
- ³Note that the risk factor data were originally collected for population-level analyses and may not be
- 728 conclusive on individual level.
- 729 CVST, cerebral venous sinus thrombosis; VITT, vaccine-induced immune thrombotic thrombocytopenia

- 732 Table 4. Causes of death in cases with suspected relationship between COVID-19 vaccination and
- 733 death prior to autopsy but with no vaccine etiology considered after medicolegal autopsy.

Cause of death	Number of cases (%)	
Disease	62 (92.5)	
Cardiovascular diseases	43 (64.2)	
Acute myocardial infarction	9 (13.4)	
Arrhythmia	1 (1.5)	
• Other / unknown mechanism	33 (49.3)	
Cerebrovascular diseases	2 (3.0)	
Alcohol-related diseases	1 (1.5)	
Gastroenterological diseases	3 (4.5)	
Malignancies	2 (3.0)	
Pulmonary embolism	5 (7.5)	
Pulmonary diseases	2 (3.0)	
Endocrinopathies and nutritional diseases	2 (3.0)	
Neurodegenerative diseases and dementia	2 (3.0)	
Accident	4 (6.0)	
Undetermined	1 (1.5)	
Total	67 (100.0)	

735 Table 5. Data on demographics, vaccinations, and pre-existing health conditions.

	COVID-19 vaccine considered	Suspicion of a relationship	Exposed
	as etiology for any cause of	between COVID-19 vaccine	population
	death after medicolegal autopsy	and death prior to	
		medicolegal autopsy	
End of follow-up	Death	Death	Dec 31, 2021
Number of cases	12	76	4,345,346
Sex			
Men	6	34	2,100,677
Women	6	42	2,244,669
Age, years		<u> </u>	
< 18	0	0	323,599
18–34	2	4	930,650
35–64	5	23	1,888,942
≥ 65	5	49	1,202,155
Most recent vaccine d	ose of the deceased vs. population vaccin	nated with cumulative number of	fdoses
1	4	45	4,345,346
2	4	19	4,135,987
3	4	9	1,265,677
4	0	0	3,042
Vaccinations			

ChAdOx1	2	19	553,426
BNT162b2	10	46	7,909,387
mRNA-1273	0	8	1,285,369
Ad26.COV2.S	0	1	206
Other	0	0	1,664
Total			9,750,052
		10	2 228 045
Number of pre-existing r	isk factors ²	19	3,328,945
		19 15	3,328,945 804,011
0	5		
0	5 3	15	804,011
1	5 3 2	15 17	804,011 176,518

¹ Date for calculating age at first dose.

² Pre-existing risk factors up until the first given vaccine dose, (each as 0 or 1): cardiovascular diseases, cognitive disorders, other neurological disorders, diabetes, chronic kidney diseases, chronic liver diseases,

pulmonary diseases, immunosuppressive diseases, Addison's disease, schizophrenia, and Down syndrome

